| 1 | EHJ ACVC where translational science meets care | 0.9 | 0 | Citations (PDF) |
| 2 | Looking back, moving forward: a bold start to 2025 | 0.9 | 0 | Citations (PDF) |
| 3 | Cracking the clot: the RIVAWAR trial challenges warfarin’s reign in left ventricular thrombus post-acute coronary syndrome | 0.9 | 1 | Citations (PDF) |
| 4 | One-Year Outcomes After Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: A Prespecified Analysis of the SWISS-APERO Randomized Clinical Trial | 13.1 | 27 | Citations (PDF) |
| 5 | Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of Cardiology guidelines | 0.9 | 14 | Citations (PDF) |
| 6 | As we reflect on the year 2023……. | 0.9 | 1 | Citations (PDF) |
| 7 | Acute cardiovascular and intensive care chronicles: ‘inception revealed—navigating the veno-arterial extracorporeal membrane oxygenation terrain and beyond’ | 0.9 | 0 | Citations (PDF) |
| 8 | March 2024 issue of the<i>European Heart Journal Acute Cardiovascular Care</i> | 0.9 | 0 | Citations (PDF) |
| 9 | European practices on antithrombotic management during percutaneous mechanical circulatory support in adults: a survey of the Association for Acute CardioVascular Care of the ESC and the European branch of the Extracorporeal Life Support Organization | 0.9 | 11 | Citations (PDF) |
| 10 | Acute cardiac and intensive care chronicles: navigating the intersection of cardiovascular health, recreational drug use, and beyond! | 0.9 | 0 | Citations (PDF) |
| 11 | Comparison of 1-month vs. 12-month dual antiplatelet therapy after implantation of drug-eluting stents in patients with acute coronary syndrome: the ULTIMATE-DAPT trial | 0.9 | 1 | Citations (PDF) |
| 12 | Acute cardiovascular and intensive care chronicles: crossing new frontiers in advanced cardiovascular therapeutics | 0.9 | 0 | Citations (PDF) |
| 13 | Unveiling new horizons: revolutionary insights into acute myocarditis and optimal mechanical circulatory support timing | 0.9 | 0 | Citations (PDF) |
| 14 | Editor’s chronicles: redefining pathways in acute cardiac care | 0.9 | 0 | Citations (PDF) |
| 15 | Revolutionizing cardiac care: insights into shock prognosis, myocardial infarction management, and platelet inhibition | 0.9 | 0 | Citations (PDF) |
| 16 | Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome | 13.1 | 41 | Citations (PDF) |
| 17 | Should renin–angiotensin system inhibitors be stopped or not before non-cardiac surgery? | 0.9 | 2 | Citations (PDF) |
| 18 | Resilience and renewal: charting the future of cardiovascular care in a changing world | 0.9 | 1 | Citations (PDF) |
| 19 | Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials | 2.6 | 20 | Citations (PDF) |
| 20 | On the brink of the new year, on the brink of a new era: <i>European Heart Journal Acute CardioVascular Care</i> goes online only | 0.9 | 0 | Citations (PDF) |
| 21 | Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC) | 2.6 | 36 | Citations (PDF) |
| 22 | BIOVASC trial in perspective: complete revascularization strategies in patients presenting with acute coronary syndromes and multi-vessel coronary disease | 0.9 | 1 | Citations (PDF) |
| 23 | Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium | 13.1 | 169 | Citations (PDF) |
| 24 | MULTi-vessel Immediate vs. STAged RevaScularization in Acute Myocardial Infarction: the MULTISTARS AMI trial | 0.9 | 0 | Citations (PDF) |
| 25 | Generalized Pairwise Comparisons to Assess Treatment Effects | 0.7 | 32 | Citations (PDF) |
| 26 | Coronary calcification in patients presenting with acute coronary syndromes: insights from the MATRIX trial | 0.9 | 9 | Citations (PDF) |
| 27 | Editors' perspective | 0.9 | 0 | Citations (PDF) |
| 28 | Edoxaban and/or colchicine in outpatients with COVID-19: rationale and design of the CONVINCE trial | 0.9 | 3 | Citations (PDF) |
| 29 | PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY | 2.6 | 60 | Citations (PDF) |
| 30 | Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial | 13.1 | 137 | Citations (PDF) |
| 31 | Appointment as patient advocacy associate editor | 0.9 | 2 | Citations (PDF) |
| 32 | Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug‐Eluting Stent Implantation: Per‐Protocol Analysis of the GLOBAL LEADERS Trial | 3.1 | 9 | Citations (PDF) |
| 33 | Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock | 0.7 | 102 | Citations (PDF) |
| 34 | Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis | 2.6 | 78 | Citations (PDF) |
| 35 | P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention | 24.5 | 73 | Citations (PDF) |
| 36 | Acetazolamide for patients with acute decompensated heart failure with volume overload | 0.9 | 3 | Citations (PDF) |
| 37 | Acute cardiovascular care in the emergency department and beyond: a call for interdisciplinary collaboration in clinical research | 0.9 | 2 | Citations (PDF) |
| 38 | Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials | 2.6 | 42 | Citations (PDF) |
| 39 | 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation | 2.6 | 4,436 | Citations (PDF) |
| 40 | European Heart Journal – Acute Cardiovascular Care moving onwards and upwards | 0.9 | 0 | Citations (PDF) |
| 41 | Predicting 2‐year all‐cause mortality after contemporary PCI: Updating the logistic clinical SYNTAX score | 1.1 | 8 | Citations (PDF) |
| 42 | Comparison of Investigator-Reported and Clinical Event Committee–Adjudicated Outcome Events in GLASSY | 2.8 | 11 | Citations (PDF) |
| 43 | Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management | 1.9 | 41 | Citations (PDF) |
| 44 | SPOT the DIAGNOSIS | 0.9 | 0 | Citations (PDF) |
| 45 | Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond | 2.6 | 4 | Citations (PDF) |
| 46 | Design and Rationale of the Swiss-Apero Randomized Clinical Trial: Comparison of Amplatzer Amulet vs Watchman Device in Patients Undergoing Left Atrial Appendage Closure | 1.3 | 15 | Citations (PDF) |
| 47 | External validation of the
GRACE
risk score 2.0 in the contemporary
all‐comers GLOBAL LEADERS
trial | 1.1 | 1 | Citations (PDF) |
| 48 | Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR | 19.4 | 257 | Citations (PDF) |
| 49 | Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk | 19.4 | 552 | Citations (PDF) |
| 50 | Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial | 13.1 | 76 | Citations (PDF) |
| 51 | Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre‐Specified Analysis of the GLOBAL LEADERS Trial | 3.1 | 48 | Citations (PDF) |
| 52 | The multiplication of loaves and fishes approach: a critic todoubleanti-thrombotics or todoublenumber of ischaemic events? | 2.6 | 1 | Citations (PDF) |
| 53 | Clinical relevance of ticagrelor monotherapy following 1‐month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial | 1.1 | 19 | Citations (PDF) |
| 54 | Atrial fibrillation patients undergoing percutaneous coronary intervention: dual or triple antithrombotic therapy with non-vitamin K antagonist oral anticoagulants | 0.2 | 5 | Citations (PDF) |
| 55 | Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial | 1.6 | 7 | Citations (PDF) |
| 56 | Safety and Efficacy of Double Antithrombotic Therapy With Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis | 3.1 | 73 | Citations (PDF) |
| 57 | Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial | 2.6 | 27 | Citations (PDF) |
| 58 | Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention | 3.2 | 29 | Citations (PDF) |
| 59 | Respiratory management in severe acute respiratory syndrome coronavirus 2 infection | 0.9 | 23 | Citations (PDF) |
| 60 | United we stand, divided we fall | 0.9 | 1 | Citations (PDF) |
| 61 | Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest | 0.2 | 7 | Citations (PDF) |
| 62 | Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction | 13.1 | 96 | Citations (PDF) |
| 63 | Higher risk of stent thrombosis with double therapy with direct oral anticoagulants: cherry picking the populations of interest does not help | 2.6 | 4 | Citations (PDF) |
| 64 | DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI | 1.9 | 19 | Citations (PDF) |
| 65 | Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis | 1.4 | 19 | Citations (PDF) |
| 66 | 2018 ESC/EACTS Guidelines on myocardial revascularization | 2.6 | 6,237 | Citations (PDF) |
| 67 | Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC) | 2.6 | 83 | Citations (PDF) |
| 68 | Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial | 2.6 | 125 | Citations (PDF) |
| 69 | Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials | 2.6 | 306 | Citations (PDF) |
| 70 | Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting | 0.7 | 145 | Citations (PDF) |
| 71 | Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI | 0.7 | 28 | Citations (PDF) |
| 72 | Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial | 45.2 | 643 | Citations (PDF) |
| 73 | Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes | 9.3 | 136 | Citations (PDF) |
| 74 | Association of acute kidney injury and bleeding events with mortality after radial or femoral access in patients with acute coronary syndrome undergoing invasive management: secondary analysis of a randomized clinical trial | 2.6 | 27 | Citations (PDF) |
| 75 | Physical manoeuvers as a preventive intervention to manage vasovagal syncope: A systematic review | 1.5 | 18 | Citations (PDF) |
| 76 | Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY) | 1.2 | 22 | Citations (PDF) |
| 77 | Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study | 1.8 | 62 | Citations (PDF) |
| 78 | Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates | 1.6 | 4 | Citations (PDF) |
| 79 | Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial | 1.4 | 4 | Citations (PDF) |
| 80 | Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management | 1.9 | 62 | Citations (PDF) |
| 81 | Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial | 1.8 | 84 | Citations (PDF) |
| 82 | 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS | 2.6 | 2,716 | Citations (PDF) |
| 83 | 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS | 1.2 | 319 | Citations (PDF) |
| 84 | The Significance of Drug–Drug and Drug–Food Interactions of Oral Anticoagulation | 2.4 | 120 | Citations (PDF) |
| 85 | Integrating the results of the CULPRIT-SHOCK trial in the 2017 ESC ST-elevation myocardial infarction guidelines: viewpoint of the task force | 2.6 | 31 | Citations (PDF) |
| 86 | Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention | 24.5 | 207 | Citations (PDF) |
| 87 | Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial | 45.2 | 750 | Citations (PDF) |
| 88 | Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document | 13.1 | 848 | Citations (PDF) |
| 89 | Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium | 1.8 | 20 | Citations (PDF) |
| 90 | Thrombo-embolic prevention after transcatheter aortic valve implantation | 2.6 | 67 | Citations (PDF) |
| 91 | A Critical Appraisal of Aspirin in Secondary Prevention | 13.1 | 89 | Citations (PDF) |
| 92 | Standardization of Fractional Flow Reserve Measurements | 0.7 | 208 | Citations (PDF) |
| 93 | Clinical benefit of atrio-ventricular delay optimization in patients with a dual-chamber pacemaker: a pilot study. The CBRAVO trial (NCT01998256) | 0.9 | 0 | Citations (PDF) |
| 94 | Non-vitamin K oral anticoagulants in patients with atrial fibrillation after cardiac surgery: the results of the European Heart Rhythm Association Survey | 1.8 | 16 | Citations (PDF) |
| 95 | Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial | 1.8 | 71 | Citations (PDF) |
| 96 | Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention? | 1.9 | 154 | Citations (PDF) |
| 97 | Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial | 2.6 | 81 | Citations (PDF) |
| 98 | Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates | 0.7 | 269 | Citations (PDF) |
| 99 | Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial | 1.6 | 5 | Citations (PDF) |
| 100 | Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention | 2.2 | 10 | Citations (PDF) |
| 101 | Short- Versus Long-Term Duration of Dual Antiplatelet Therapy in Patients Treated for In-Stent Restenosis | 0.7 | 68 | Citations (PDF) |
| 102 | Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial | 2.6 | 54 | Citations (PDF) |
| 103 | 4-Year Clinical Outcomes and Predictors of Repeat Revascularization in Patients Treated With New-Generation Drug-Eluting Stents | 0.7 | 159 | Citations (PDF) |
| 104 | Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: Rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in Uncertain DES Candidates study | 1.8 | 18 | Citations (PDF) |
| 105 | Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) | 2.6 | 112 | Citations (PDF) |
| 106 | Physical fitness affects the quality of single operator cardiocerebral resuscitation in healthcare professionals | 1.1 | 36 | Citations (PDF) |
| 107 | Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting | 13.1 | 680 | Citations (PDF) |
| 108 | Darapladib effect on circulating high sensitive troponin in patients with acute coronary syndromes | 1.9 | 8 | Citations (PDF) |
| 109 | Different cardiac biomarkers to detect peri-procedural myocardial infarction in contemporary coronary stent trials: impact on outcome reportingHeart, 2012, 98, 1424-1430 | 2.6 | 27 | Citations (PDF) |
| 110 | Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial | 45.2 | 222 | Citations (PDF) |
| 111 | 5-Year Follow-Up of Coronary Revascularization in Diabetic Patients With Multivessel Coronary Artery Disease | 1.9 | 62 | Citations (PDF) |
| 112 | A Patient-Level Pooled Analysis Assessing the Impact of the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) Score on 1-Year Clinical Outcomes in 6,508 Patients Enrolled in Contemporary Coronary Stent Trials | 1.9 | 78 | Citations (PDF) |
| 113 | Standardized Bleeding Definitions for Cardiovascular Clinical Trials | 13.1 | 4,343 | Citations (PDF) |
| 114 | Preoxygenated hemoglobin-based oxygen carrier HBOC-201 annihilates myocardial ischemia during brief coronary artery occlusion in pigs | 2.2 | 28 | Citations (PDF) |
| 115 | Proof-of-concept trial to evaluate haemoglobin based oxygen therapeutics in elective percutaneous coronary revascularisation. Rationale, protocol design and haemodynamic results | 2.2 | 21 | Citations (PDF) |
| 116 | Retrogade embolization after balloon angioplasty in a patient with late stent subthrombosis in a paclitaxel-eluting stent | 0.9 | 0 | Citations (PDF) |
| 117 | Clinical introduction of the Tandemheart, a percutaneous left ventricular assist device, for circulatory support during high-risk percutaneous coronary intervention | 0.6 | 75 | Citations (PDF) |
| 118 | P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials | 0.2 | 212 | Citations (PDF) |
| 119 | DAPT-SHOCK-AMI: does faster and more complete platelet inhibition translate to improved clinical outcomes? | 0.9 | 0 | Citations (PDF) |
| 120 | The NEO-MINDSET trial: immediate aspirin withdrawal after percutaneous coronary intervention for acute coronary syndrome—remains a therapeutic no-man’s land | 0.9 | 0 | Citations (PDF) |
| 121 | Not too much, not too little: the TOP trial and the Goldilocks zone of transfusion | 0.9 | 0 | Citations (PDF) |
| 122 | Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome | 13.1 | 2 | Citations (PDF) |
| 123 | Where evidence becomes action | 0.9 | 0 | Citations (PDF) |
| 124 | When neutral is not positive, and not definitive: CHIP-BCIS3 and the selective use of mechanical support in high-risk PCI | 0.9 | 0 | Citations (PDF) |
| 125 | Strike early, strike strong | 0.9 | 1 | Citations (PDF) |
| 126 | Impact of guidelines-directed very-high-risk criteria in the identification and management of occlusion myocardial infarction in patients with NSTE-ACS | 0.9 | 0 | Citations (PDF) |
